Teva Pharmaceutical Industries Limited (TLV:TEVA)
5,587.00
+7.00 (0.13%)
Mar 31, 2025, 5:24 PM IDT
TLV:TEVA Revenue
In the year 2024, Teva Pharmaceutical Industries had annual revenue of $16.54B USD with 4.40% growth. Teva Pharmaceutical Industries had revenue of $4.23B in the quarter ending December 31, 2024, a decrease of -5.12%.
Revenue
$16.54B
Revenue Growth
+4.40%
P/S Ratio
n/a
Revenue / Employee
$463.60K
Employees
35,686
Market Cap
65.58B ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Danel (Adir Yeoshua) | 2.77B |
Kamada | 586.24M |
Bait Bakfar | 102.08M |
Novolog (Pharm-Up 1966) | 2.02B |
Ilex Medical | 982.96M |
BrainsWay | 149.39M |
SofWave Medical | 217.27M |
Golden House | 47.96M |
Teva Pharmaceutical Industries News
- 8 hours ago - New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable - Financial Post
- 8 hours ago - New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable - GlobeNewsWire
- 4 days ago - Teva Releases Q1 2025 Aide Memoire - Benzinga
- 4 days ago - Teva Releases Q1 2025 Aide Memoire - GlobeNewsWire
- 4 days ago - Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025 - GlobeNewsWire
- 4 days ago - Teva Pharmaceutical Indus Unusual Options Activity - Benzinga
- 11 days ago - Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript - GuruFocus
- 11 days ago - Teva Pharmaceutical Industries Ltd to Discuss New Data Presented for Duvakitug (Anti-TL1A) ... - GuruFocus